Reports Q4 revenue $32.7M, consensus $33.4M. “In 2023, as the pharmaceutical industry was rationalizing spend and capex, our low margin slow-growth freezer franchise was obfuscating the value of BioLife’s high-margin, class-defining consumable bioproduction media, tools, and services. In Q4 we saw a double-digit sequential increase in our core cell processing revenues and the commencement of the divestiture, with the goal of finalizing a sale by the end of the first quarter” said Roderick de Greef, CEO. “The divestiture matched with a doubling down on our higher margin recurring revenue streams will have an immediate and positive impact on our financial profile. Add to this, early signs from our business leaders and customers of industry clouds clearing, we expect similar momentum into 2024 and the potential for accelerating growth in the back of the year.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results
- BLFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioLife Solutions price target raised to $20 from $15 at Lake Street
- BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
- BioLife Solutions sees FY23 revenue $143.3M, consensus $144.37M